SCHEMBL10061877

SCHEMBL10061877

COc1cc([C@@H]2c3cc4c(cc3[C@@H](O[C@@H]3OC5CO[C@@H](C)O[C@H]5[C@@H](O)C3O)[C@H]3COC(=O)[C@H]23)OCO4)cc(CO)c1O

nearest known ligand 0.89

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CYP3A4 P08684 6/20 0.89
GAA P10253 5/20 0.89
SMN1; SMN2 Q16637 5/20 0.89
TOP2A P11388 5/20 0.89
TOP2B Q02880 4/20 0.89
LMNA P02545 3/20 0.89
MEN1 O00255 2/20 0.89
KMT2A Q03164 2/20 0.89
NCOA3 Q9Y6Q9 2/20 0.89
HSD17B10 Q99714 2/20 0.89
HIF1A Q16665 2/20 0.89
CYP1A2 P05177 1/20 0.89
CYP2D6 P10635 1/20 0.89
CYP2C9 P11712 1/20 0.89
CYP2C19 P33261 1/20 0.89
NCOA1 Q15788 1/20 0.89
SLCO1B3 Q9NPD5 1/20 0.89
ATM Q13315 1/20 0.68
USP2 O75604 1/20 0.68
ABCC3 O15438 1/20 0.68

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL13818627 1.00 CYP3A4 (0.89) CYP3A4GAASMN1; SMN2TOP2ATOP2B
SCHEMBL422175 1.00 CYP3A4 (0.89) CYP3A4GAASMN1; SMN2TOP2ATOP2B
SCHEMBL15472841 1.00 CYP3A4 (0.89) CYP3A4GAASMN1; SMN2TOP2ATOP2B
SCHEMBL19959379 1.00 CYP3A4 (0.89) CYP3A4GAASMN1; SMN2TOP2ATOP2B
SCHEMBL17816434 1.00 CYP3A4 (0.89) CYP3A4GAASMN1; SMN2TOP2ATOP2B
SCHEMBL94972 0.94 CYP3A4 (0.81) CYP3A4GAASMN1; SMN2TOP2ATOP2B
SCHEMBL15060571 0.94 CYP3A4 (0.81) CYP3A4GAASMN1; SMN2TOP2ATOP2B
SCHEMBL12308351 0.94 CYP3A4 (0.81) CYP3A4GAASMN1; SMN2TOP2ATOP2B
SCHEMBL16606226 0.94 CYP3A4 (0.81) CYP3A4GAASMN1; SMN2TOP2ATOP2B
Etoposide SCHEMBL24482748 0.94 CYP3A4 (1.00) CYP3A4GAASMN1; SMN2TOP2ATOP2B

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-10034851-B2 Metal-salen complex compound, local anesthetic and antineoplastic drug IHI CORPORATION (JP) 2018-07-31 US disclosed
US-9505732-B2 Auto magnetic metal salen complex compound IHI CORPORATION (JP) 2016-11-29 US disclosed
US-20160263074-A1 METAL-SALEN COMPLEX COMPOUND, LOCAL ANESTHETIC AND ANTINEOPLASTIC DRUG ISHIKAWA YOSHIHIRO (JP) 2016-09-15 US disclosed
US-20140206635-A1 METAL-SALEN COMPLEX COMPOUND, LOCAL ANESTHETIC AND ANTINEOPLASTIC DRUG IHI CORPORATION (JP) 2014-07-24 US disclosed
US-20140046021-A1 SELF-MAGNETIC METAL-SALEN COMPLEX COMPOUND IHI CORPORATION (JP) 2014-02-13 US disclosed
US-20120029167-A1 AUTO MAGNETIC METAL SALEN COMPLEX COMPOUND YOSHIHIRO ISHIKAWA (JP) 2012-02-02 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120029167-A1 AUTO MAGNETIC METAL SALEN COMPLEX COMPOUND SDHB, SDHA, SLC40A1 CYP3A4 1697/4885GAA 65/4885SMN1; SMN2 114/4885
US-20140206635-A1 METAL-SALEN COMPLEX COMPOUND, LOCAL ANESTHETIC AND ANTINEOPLASTIC DRUG NCLN, KCNN2, NCSTN CYP3A4 1870/4885GAA 2194/4885SMN1; SMN2 93/4885
US-10034851-B2 Metal-salen complex compound, local anesthetic and antineoplastic drug NCLN, KCNN2, NCSTN CYP3A4 1870/4885GAA 2194/4885SMN1; SMN2 93/4885
US-20140046021-A1 SELF-MAGNETIC METAL-SALEN COMPLEX COMPOUND SSBP1, KCNN1, IMMT CYP3A4 2664/4885GAA 879/4885SMN1; SMN2 308/4885
US-20160263074-A1 METAL-SALEN COMPLEX COMPOUND, LOCAL ANESTHETIC AND ANTINEOPLASTIC DRUG NCLN, KCNN2, NCSTN CYP3A4 1870/4885GAA 2194/4885SMN1; SMN2 93/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.